572924-00-6

Basic information

• Product Name: (S)-2-CYCLOPENTYLOXYCARBONYLAMINO-3,3-DIMETHYL-BUTYRIC ACID
• Synonyms: L-Valine, N-[(cyclopentyloxy)carbonyl]-3-Methyl;N-[(cyclopentyloxy)carbonyl]-L-tert-leucine;(S)-2-(((CYCLOPENTYLOXY)CARBONYL)AMINO)-3,3-DIMETHYLBUTANOIC ACID
• CAS NO: 572924-00-6
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Mol File: 572924-00-6.mol

Chemical Properties

• Boiling Point: 392.6°C at 760 mmHg
• Flash Point: 191.2°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 2.95E-07mmHg at 25°C
• Refractive Index: 1.493
• CAS DataBase Reference: (S)-2-CYCLOPENTYLOXYCARBONYLAMINO-3,3-DIMETHYL-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-CYCLOPENTYLOXYCARBONYLAMINO-3,3-DIMETHYL-BUTYRIC ACID(572924-00-6)
• EPA Substance Registry System: (S)-2-CYCLOPENTYLOXYCARBONYLAMINO-3,3-DIMETHYL-BUTYRIC ACID(572924-00-6)

Safety Data

• Hazardous Substances Data: 572924-00-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and functional groups make it a valuable building block in the development of new medications.
Used in Chemical Research:
(S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is used as a research compound in the field of organic chemistry. Its various functional groups allow for the study of different chemical reactions and the development of new synthetic methods.
Used in Biochemical Studies:
(S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is used in biochemical research to investigate the role of amino acids and their derivatives in biological systems. Its unique structure can provide insights into the mechanisms of various biological processes.
Used in Industrial Applications:
(S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyric acid is used in various industrial applications due to its versatile chemical properties. Its functional groups can be utilized in the synthesis of different types of compounds, making it a valuable component in the production of various products.

InChI:InChI=1/C12H21NO4/c1-12(2,3)9(10(14)15)13-11(16)17-8-6-4-5-7-8/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)/t9-/m1/s1

Upstream product

• 20859-02-3 L-tert-Leucine 
• 50715-28-1 cyclopentyl chloroformate 
• 96-41-3 Cyclopentanol 
• 128595-07-3 carbonic acid cyclopentyl ester 2,5-dioxopyrrolidin-1-yl ester 

Downstream Products

• 572924-76-6 N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4S)-N-[(1R,2S)-2-ethenyl-1-(methoxycarbonyl)cyclopropyl]-4-hydroxy-L-prolinamide 
• 921790-38-7 C₂₄H₃₃BrN₂O₈S 
• 877069-24-4 methyl N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolinate 
• 877069-25-5 (2S,4R)-1-((S)-2-(cyclopentyloxycarbonylamino)-3,3-dimethylbutanoyl)-4-hydroxy-pyrrolidine-2-carboxylic acid 
• 99465-82-4 (2S,4R)-methyl 4-hydroxy-1-pivaloylpyrrolidine-2-carboxylate 
• 872496-96-3 C₃₁H₄₀N₄O₁₀ 
• 872497-29-5 C₃₃H₄₃N₃O₇ 
• 877068-88-7 (2S,4R)-1-((S)-2-Cyclopentyloxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester 
• 877068-97-8 C₃₆H₄₃N₃O₉ 

Relevant articles and documents

Highly efficient carbamate formation from alcohols and hindered amino acids or esters using N, N′-disuccinimidyl carbonate (DSC)

A highly efficient and straightforward protocol to prepare carbamates from alcohols and hindered amino acids/esters mediated by N,N′-disuccinimidyl carbonate (DSC) in the presence of catalytic amount of pyridine is described. This method could be carried out under mild conditions in one pot, and a wide variety of carbamates were obtained in high yield with excellent purity. Georg Thieme Verlag Stuttgart - New York.

Inhibitors of Serine Proteases

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)

C-Terminal carboxylic acid containing inhibitors of the NS3 protease are reported. A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described. A substantial contribution to the potency of these

INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.

INHIBITORS OF SERINE PROTEASES

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.

HEPATITIS C INHIBITOR PEPTIDE ANALOGS

The invention relates to compounds of formula (I) wherein R', R2, R3, R4, R5, R6, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).

Substituted cycloalkyl P1' hepatitis C virus inhibitors

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compound

Compounds of formula (I): wherein B, X, R3, R21, R22, R1 and Rc are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.